Related references
Note: Only part of the references are listed.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng et al.
LEUKEMIA (2017)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R. Hajek et al.
LEUKEMIA (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
Hang Quach et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Meletios A. Dimopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD ADVANCES (2017)
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
Eli Muchtar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors
Sophia Danhof et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
James R. Berenson et al.
BLOOD (2016)
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Herve Avet-Loiseau et al.
BLOOD (2016)
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Susan J. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A practical review on carfilzomib in multiple myeloma
Eli Muchtar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma
Xuemei Cai et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
G. P. Soriano et al.
LEUKEMIA (2016)
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
A. Rosenthal et al.
BLOOD CANCER JOURNAL (2016)
Carfilzomib for treating myeloma
Dimitrios C. Ziogas et al.
EXPERT OPINION ON ORPHAN DRUGS (2016)
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
B. Franken et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2015)
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
David H. Vesole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma
Pierre Squifflet et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
S. Atrash et al.
BLOOD CANCER JOURNAL (2015)
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
Fabrizio Accardi et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Pieter Sonneveld et al.
BLOOD (2015)
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
Nikoletta Lendvai et al.
BLOOD (2014)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Q. Ping Dou et al.
CURRENT CANCER DRUG TARGETS (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
J. R. Berenson et al.
LEUKEMIA (2014)
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma
Elisabet E. Manasanch et al.
LEUKEMIA & LYMPHOMA (2014)
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Teresa S. Hawley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang et al.
BLOOD (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
A. Z. Badros et al.
LEUKEMIA (2013)
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
Zhengping Wang et al.
DRUG METABOLISM AND DISPOSITION (2013)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Melissa Alsina et al.
CLINICAL CANCER RESEARCH (2012)
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
D. J. Kuhn et al.
CURRENT CANCER DRUG TARGETS (2011)
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Michel Delforge et al.
LANCET ONCOLOGY (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
